US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 1.090
- -0.030-2.68%
Close Jan 17 16:00 ET
- 1.120
- +0.030+2.75%
Post 19:39 ET
25.32MMarket Cap-1.43P/E (TTM)
1.120High1.050Low83.66KVolume1.100Open1.120Pre Close91.98KTurnover0.74%Turnover RatioLossP/E (Static)23.23MShares2.33052wk High-9.01P/B12.39MFloat Cap0.51252wk Low--Dividend TTM11.37MShs Float8.180Historical High--Div YieldTTM6.24%Amplitude0.400Historical Low1.099Avg Price1Lot Size
NeuroSense Therapeutics Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
64
25
13
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
Monday, 6th January at 9:00 am
• NeuroSense in Compliance with all Nasdaq Listing Requirements
CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nas...
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
Monday, 6th January at 9:00 am
• NeuroSense in Compliance with all Nasdaq Listing Requirements
CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nas...
1
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Monday, 23rd December at 9:00 am
• Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study
• Additionally, milestone payments and double-digit royalties on annual net sales
• The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025
CAMBRIDGE, Mass., Dec. 23, 2024 /...
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Monday, 23rd December at 9:00 am
• Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study
• Additionally, milestone payments and double-digit royalties on annual net sales
• The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025
CAMBRIDGE, Mass., Dec. 23, 2024 /...
1
$NeuroSense Therapeutics (NRSN.US)$ Finally but seems to be fitting a pattern lately! PR then a day to a week later, then moves! Hehehe![]()
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Therapeutics: Initiated the Regulatory Process to Seek Early Commercialization Approval for PrimeC Under Health Canada >NRSN
Dow Jones· 7 mins ago
Dow Jones· 7 mins ago
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
Wednesday, 11th December at 9:25 am
• The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025
• PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS
CAMBRIDGE, Mass., Dec. 11, 2024 /PRNe...
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
Wednesday, 11th December at 9:25 am
• The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025
• PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS
CAMBRIDGE, Mass., Dec. 11, 2024 /PRNe...
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Announces PARADIGM Study Results Showing PrimeC Slows ALS Progression By 33% And Improves Survival By 58%, Redefining Potential Standard Of Care In ALS Treatment
Benzinga· 4 mins ago
Benzinga· 4 mins ago
$NeuroSense Therapeutics (NRSN.US)$ In connection with the offering, NeuroSense agreed to sell an aggregate of 4,000,000 ordinary shares (or ordinary share equivalents) and 8,000,000 warrants to purchase an aggregate of 8,000,000 ordinary shares, at a combined purchase price of $1.25 per share and two accompanying warrants, representing a purchase price of 25% above the closing pricing of NeuroSense's ordinary shares on November 29, 2024. The warrants have a term of five ye...
1
4
$NeuroSense Therapeutics (NRSN.US)$ Reuters· 2 mins ago
Neurosense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
Neurosense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Carlos Moreno138 : j8 on vrax, no cash on had what do you mien with that?
Jaguar8 OP Carlos Moreno138 : They don’t have cash to operate on
Carlos Moreno138 : so they are probably going to diluted
原来是你啊 : I don't understand why. $Intelligent Protection Managem (IPM.US)$ No volume.
Jaguar8 OP Carlos Moreno138 : Yes but they pump before dilution. That is what is happening for most stocks. Why? Because it adds cushion for it before it plummets to still satisfy price bid requirement
View more comments...